JNJ Dividend Outshines MRK as Patent Cliff Looms

Investors seeking dividend-paying pharmaceutical stocks for their retirement portfolios may want to focus on Johnson & Johnson (JNJ) over Merck (MRK), according to an analysis of their performance and prospects. Both companies have seen significant gains this year, with MRK up 40.18% and JNJ up 29.1%. However, a closer look at their dividend histories, patent cliff exposure, and balance sheet risks reveals that JNJ may be the more reliable choice.

JNJ has consistently raised its dividend every year since 2009, with the most recent increase to $1.34 per quarter in April 2026. In contrast, MRK's dividend history includes a flat period from 2010 to 2011 and only recently stepped up from $0.81 to $0.85 per quarter.

Moreover, JNJ has a stronger record of generating free cash flow, with $19.7 billion in 2025 and guidance for a full-year figure approaching $21 billion. MRK's management has expressed commitment to its dividend but failed to provide any payout ratio or free cash flow figures.

In terms of patent cliff exposure, JNJ is currently navigating this challenge, having seen a significant decline in Stelara sales, but its overall sales have still grown. In contrast, MRK relies heavily on Keytruda, which represents nearly half of its revenue and has faced declining growth rates, with recent Phase 3 trials yielding disappointing results.

Finally, JNJ's balance sheet is more conservative, with a net debt position near $28 billion compared to MRK's self-inflicted burden of combined one-time charges from recent deals, which total around $14.8 billion and have pushed full-year other expense to about $1.4 billion.